-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
July 20, Hengrui Medicine announced that its innovative drugs approved clinical SHR-1906 for special idiopathic pulmonary fibrosis of (IPF )
Increasing incidence and limited treatment options.
The process of IPF is irreversible, and the prognosis is extremely poor.
Pirfenidone is the world's first marketed drug for the treatment of IPF.
Nintanib was developed by Boehringer Ingelheim and was approved in the United States in October 2014.
List of products under research
(Data as of July 20, 2021)
Renfu Medicine
AGCO
Haisco
FTP-198is a self-developed Hai Sike a new class of IPF for drugs belonging toautotaxin inhibitor
Dongyang Sunshine Pharmaceutical
Jing Ze Pharmaceutical Ze Jing class of innovative pharmaceutical drugs hydrochloride Jack imatinib in January 2020 in the domestic clinical approval, is the first approved for the treatment of IPF JAK inhibitor class of drugs, the same year started July 2 Clinical.
Zhongsheng Pharmaceutical
Zhongsheng Pharmaceutical's first-class innovative drug ZSP1603 was approved for clinical use in China in October 2017.
It is the first small molecule innovative drug approved for clinical use in the treatment of IPF and malignant tumors at the same target site in China.
It has been completed.
Phase I clinical trial
.
Pre-clinical data show that ZSP1603 has better anti-pulmonary fibrosis effect than nintedanib, and it has better drug safety
.
Tianfang Pharmaceutical
Tianfang Pharmaceutical's first-class innovative drug YPS345 was approved for clinical use in China in January 2019 for the treatment of pneumonia and pulmonary fibrosis caused by thoracic radiotherapy in tumor patients.
At present, its phase 1 clinical trial has been completed
.
Previously, preclinical trials have shown that YPS345 has a significant alleviating effect on pulmonary fibrosis induced by radiotherapy and chemotherapy, and has good safety
.
Hengrui Pharmaceuticals
Hengrui Pharmaceuticals currently has two clinical trials for IPF indications.
The earliest famitinib malate initiated a phase 1 clinical trial in 2015
.
Famitinib malate is a multi-target tyrosine kinase inhibitor and has also been approved for clinical trials in a variety of cancer types
.
In addition, this is SHR-1906, the first clinical indication for this product to be approved is IPF
.
Hengrui's research and development is progressing very fast, and the Phase I clinical trial was announced yesterday
.
SHR-1906 clinical trial details
From Insight database (http://db.
dxy.
cn/v5/home/)
References: [1] He Xiaoyun, Hou Yijun, Qin Fang, Zhang Nan, Li Jing, Zhou Yunzhi, Guo Yang.
Rehabilitation of severe SARS with integrated traditional Chinese and Western medicine Analysis of changes in lung function of patients in 2 and a half years after illness[J] .
World Science and Technology (Modernization of Traditional Chinese Medicine) , 2011 , 13(02):253-258.
